Data as of Oct 24
| -0.10 / -0.75%|
The 8 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 18.50, with a high estimate of 21.00 and a low estimate of 11.00. The median estimate represents a +40.68% increase from the last price of 13.15.
The current consensus among 9 polled investment analysts is to Buy stock in Nektar Therapeutics. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.